To include your compound in the COVID-19 Resource Center, submit it here.
Vertex Pharmaceuticals Inc.
Cowen & Co. analyst David Stone said the Cambridge, Mass., company's HIV protease inhibitor,
, is potentially superior to Merck's drug.
In 28-day primate studies, VX-478 was
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury